title: [Survival benefit from the addition of bevacizumab to first-line radiochemotherapy for the treatment of proneural glioblastoma?].
authors.affiliation: Universitätsklinikum Leipzig, Stephanstraße 9a, 04103, Leipzig, Deutschland.
authors.forename: Clemens
authors.initials: C
authors.lastname: Seidel
authors.affiliation: Universitätsklinikum Leipzig, Stephanstraße 9a, 04103, Leipzig, Deutschland. Rolf-Dieter.Kortmann@medizin.uni-leipzig.de.
authors.forename: Rolf-Dieter
authors.initials: RD
authors.lastname: Kortmann
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D003606:Dacarbazine / Q000031:analogs & derivatives*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D008297:Male
chemical_list: D020533:Angiogenesis Inhibitors; D018906:Antineoplastic Agents, Alkylating; D000068258:Bevacizumab; D003606:Dacarbazine